PL EN


2018 | 21 | 5 | 81-94
Article title

The importance of “disclosure” in relationships between physicians and pharmaceutical companies

Content
Title variants
Languages of publication
EN
Abstracts
EN
The article raises issues of transparency in relationships between doctors and drug manufacturers. It indicates how important it is as a way for physicians and the pharmaceutical industry to regain public trust. The manuscript will define the concept of disclosure. It will discuss in detail The Physician Payment Sunshine Act from the U.S., which imposes a legal obligation on pharmaceutical companies to disclose their relationships with doctors and university hospitals. The article will also show the diverse regulation of disclosure in different countries of the European Union. The situation in Poland will be also described. In the summary, there will be a discussion about the importance of disclosure for patients and the advantages and disadvantages of such regulations for physicians and drug manufacturers.
Year
Volume
21
Issue
5
Pages
81-94
Physical description
Dates
published
2019-03-22
Contributors
References
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.ojs-doi-10_18778_1899-2226_21_5_07
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.